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Abstract
Background: The outcome of virus infection depends from the precise coordination of viral gene expression and
genome replication. The ability to control and regulate these processes is therefore important for analysis of
infection process. Viruses are also useful tools in bio- and gene technology; they can efficiently kill cancer cells and
trigger immune responses to tumors. However, the methods for constructing tissue- or cell-type specific viruses
typically suffer from low target-cell specificity and a high risk of reversion. Therefore novel and universal methods
of regulation of viral infection are also important for therapeutic application of virus-based systems.
Methods: Aberrantly spliced introns were introduced into crucial gene-expression units of adenovirus vector and
alphavirus DNA/RNA layered vectors and their effects on the viral gene expression, replication and/or the release of
infectious genomes were studied in cell culture. Transfection of the cells with splice-switching oligonucleotides was
used to correct the introduced functional defect(s).
Results: It was demonstrated that viral gene expression, replication and/or the release of infectious genomes can
be blocked by the introduction of aberrantly spliced introns. The insertion of such an intron into an adenovirus
vector reduced the expression of the targeted gene more than fifty-fold. A similar insertion into an alphavirus
DNA/RNA layered vector had a less dramatic effect; here, only the release of the infectious transcript was
suppressed but not the subsequent replication and spread of the virus. However the insertion of two aberrantly
spliced introns resulted in an over one hundred-fold reduction in the infectivity of the DNA/RNA layered vector.
Furthermore, in both systems the observed effects could be reverted by the delivery of splice-switching
oligonucleotide(s), which corrected the splicing defects.
Conclusions: Splice-switch technology, originally developed for genetic disease therapy, can also be used to
control gene expression of viral vectors. This approach represents a novel, universal and powerful method for
controlling gene expression, replication, viral spread and, by extension, virus-induced cytotoxic effects and can be
used both for basic studies of virus infection and in virus-based gene- and anti-cancer therapy.
Background
Viruses that infect vertebrate cells are capable of recog-
nizing host cells and executing gene expression, genome
replication and virion formation. The ability to use and
control these processes is at the origin of virus-based
gene-technology applications, such as the delivery of
transgenes or the use of viruses for vaccinal or vaccine-
carrier purposes. Based on their inherent ability to kill
cancer cells, a number of viruses have been tested as
anticancer agents, including those with double- [1,2]
and single-stranded DNA genomes [3] and viruses with
double- [4], negative- [5] and positive-stranded [6] RNA
genomes. Typically, these viruses can also infect normal
cells; engineering specificity for cancer cells is therefore
crucial. Several strategies have been tested for this pur-
pose, e.g., the creation of p53-sensitive mutants [7], the
alteration of viral receptor specificity [8,9], the use of
cancer-specific promoters in recombinant viruses [10,11]
and the regulation of gene expression in oncolytic
viruses using cellular microRNAs [12,13]. The general
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any medium, provided the original work is properly cited.shortcomings of such viral vectors are their specificity to
only certain cancer types and an attenuated oncolytic
potential. In addition, genetically modified viruses, espe-
cially those with RNA genomes, tend to revert, or com-
pensate for the introduced changes, which are usually
unfavorable for the infection cycle. Therefore, new
approaches are needed that are applicable to different
viral systems and allow for the possibility of combina-
tion with other regulation strategies without compro-
mising the anticancer properties of the vector.
Adenoviruses (family Adenoviridae)a r ec u r r e n t l yt h e
most extensively used oncolytic DNA viruses. They have
non-enveloped virions, linear double-stranded genomes
and replicate in the nucleus of infected cells [14]. Ade-
novirus gene expression, replication, virion formation
and cytotoxicity are dependent on the E1A proteins
expressed via a constitutively active promoter [15,16]. In
many engineered adenovirus vectors, including the
human adenovirus 5-based Adeasy system [17], the E1A
region has been deleted and, therefore, these vectors are
not capable of replication unless the E1A proteins are
co-expressed.
Among positive-strand RNA viruses, the alphaviruses
(family Togaviridae), including Semliki Forest virus
(SFV), represent one of the most promising candidates
for vaccine and anticancer vectors [6]. Alphaviruses
form cytoplasmic, membrane-associated replicase com-
plexes [18,19] and encode for two polyprotein precur-
sors: a nonstructural (ns) polyprotein (replicase),
translated directly from genomic RNA, and a structural
polyprotein, from subgenomic (SG) mRNA [20]. The
alphavirus-based replication-competent vectors contain
a complete viral genome and one or more foreign-pro-
tein-encoding sequences [6,21], whereas replicon vectors
lack the region coding for viral structural proteins and
are unable to spread [22]. Typically, the RNA genomes
of alphavirus-based vectors are rescued from cloned
infectious cDNA by in vitro transcription [23]. Alterna-
tively, cDNA can be flanked with eukaryotic transcrip-
tion sequences; here, rescue involves cellular
transcription by RNA polymerase II and nuclear exit of
the RNA product followed by translation and subse-
quent replication. These vectors are commonly known
as DNA/RNA layered vectors [24].
With the exception of poxviruses, all DNA viruses use
splicing for the expression of some of their mRNAs.
Therefore, the discovery that splicing patterns can be
regulated by antisense splice-switching oligonucleotides
(SSOs) [25-28] created novel possibilities for regulating
viral gene expression and replication. In contrast, posi-
tive-strand RNA viruses never utilize splicing; however,
the insertion of introns into their cDNA sequences is
often used for the construction of corresponding DNA/
RNA layered vectors [29-34]. Thus, all these viral
vectors can be engineered to contain aberrantly spliced
introns that block the expression of correct gene pro-
ducts (DNA viruses) or the rescue of infectious RNAs
(DNA/RNA layered vectors). Such introns frequently
occur in nature; for example, human beta thalassemia is
often caused by a single-nucleotide mutation within an
intronic segment of the human beta-globin gene, creat-
ing an aberrant splicing site [35,36]. Targeting aberrant
splicing sites with antisense SSOs has resulted in effi-
cient correction of splicing in both in vitro [37,38] and
in vivo models [39,40].
Here, we present evidence that insertion of aberrantly
spliced introns into the genome of a recombinant ade-
novirus vector results in severely defective marker-gene
expression. Similar manipulations of DNA/RNA layered
SFV vectors also resulted in a reduction of the rescue of
infectious transcripts. Both of these defects were
reversed by SSOs. In essence, the presence of such
introns in crucial regions of the viral vector represents a
lethal mutation and SSOs represent an artificial and effi-
cient cofactor required by the constructed vector. This
approach represents a novel, universal and powerful
method for controlling gene expression, replication, viral
spread and, by extension, virus-induced cytotoxic effects.
Methods
Cells and media
HeLa cells were grown at 37°C with 5% CO2 in Iscove’s
modified Dulbecco’s medium (IMDM; Invitrogen, Carls-
bad, CA, USA) supplemented with 10% fetal calf serum
(PAA, Pasching, Austria), 100 U/ml penicillin and 0.1
mg/ml streptomycin. HEK293 cells were grown in the
same conditions but in Dulbecco’s Modified Eagle Med-
ium (DMEM; Invitrogen). BHK-21 cells were grown in
Glasgow’s Minimal Essential Medium (GMEM; Invitro-
gen) containing 7.5% fetal calf serum, 2% tryptose phos-
phate broth (TPB), 200 mM HEPES, 100 U/ml penicillin
and 0.1 mg/ml streptomycin.
Luciferase reporters and introns designed for insertion
into DNA/RNA layered vectors
The luciferase reporter Luc7 contains a second intron
from the human beta-globin gene with a thalassemic
T705G mutation (IVS2
705). Its sequence corresponds
exactly to the reporter from the previously described
pLuc/705 plasmid [38]. All other luciferase reporters
were created by site-directed mutagenesis. To obtain
LucWT, the T705G mutation was reverted; for Luc6+7,
the mutation C654T (IVS2
654) [36] was added; and for
Luc0, the intron was deleted.
For the insertion of the wild-type (wt) or mutant
introns (with C654T, T705G or C654T + T705G muta-
tions) into SFV DNA/RNA layered vectors, the synthetic
DNA fragments running from unique XbaI (6,637) to
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eArt AG (Regensburg, Germany) and inserted into SFV
cDNA. Intron was positioned between nucleotides 6,696
and 6,697 (all nucleotide positions are given with respect
to the sequence of an infectious cDNA clone designated
pSFV4 [23]).
Construction, propagation and use of adenovirus vectors
containing luciferase reporter
Recombinant adenoviruses expressing firefly luciferase
from reporter genes containing wt or mutant introns
were constructed using the Adeasy system. The
sequences of LucWT, Luc7 or Luc6+7 reporters were
PCR amplified and cloned into the pShuttle-CMV vector
using the restriction sites KpnI and NotI. Recombination
with the Adeasy1 plasmid, transfection of HEK293 cells
and rescue of the recombinant adenovirus was per-
formed as previously described [17]. Adenovirus stocks
were propagated by one passage in HEK293 cells; virus
particles were collected, purified and titrated using an
endpoint-dilution method.
For infection experiments, HeLa cells grown on a 24-
well plate (with a growth area of 2 cm
2 per well) to 80%
confluence were infected with virus stock at 0.5 PFU/
cell in 200 μl serum-free IMDM media. Cells were incu-
bated with the virus for 2 h at 37°C, after which 1 ml of
complete IMDM media was added. Cells were incubated
for an additional 24 h at 37°C, collected and lysed, and
luciferase activity was then measured using a Luciferase
assay system (Promega, Madison, WI, USA).
Construction of SFV DNA/RNA layered replicon and
replication-competent vectors
Recombinant SFV DNA/RNA layered-replicon and
replication-competent vector plasmids were based on
the previously described pCMV-SFV1 and pCMV-SFV4
[29], respectively. The luciferase gene with an intron
was inserted into the region of the cDNA corresponding
to the nsP3 gene of SFV [41]. In the case of vectors
with two introns, the second intron was inserted into
the cDNA region corresponding to the SFV nsP4 gene.
If the primary transcript remains unspliced or is aber-
rantly spliced, these introns interrupt the reading frame
encoding for viral replicase, resulting in a lethal defect.
The combinations of inserted introns and the designa-
tions of the corresponding vectors are listed in Table 1.
In DNA/RNA layered replicon vectors, the sequence
encoding for EGFP was placed under the control of the
SFV SG promoter so its expression was strictly depen-
dent on the ability of the vector to initiate RNA replica-
tion and transcription in transfected cells. In addition,
variants from all replicon vectors were prepared by the
introduction of a frame-shift (FS) mutation (4 b inser-
tion) into the replicase region (at position 6,138) of SFV.
The designs of all the DNA/RNA layered vectors are
shown in Figure 1 and the sequences of all vectors and
details of their construction are available from the
authors on request.
Antisense oligonucleotides and transfection procedures
Phosphorothioate 2’’-OMe RNA oligonucleotides desig-
nated as ON705 (5’-CCUCUUACCUCAGUUACA-3’),
ON654 (5’-GCUAUUACCUUAACCCAG-3’)a n d
ONINV (5’-CCUCUUACACUCGUUACA-3’)[ 4 2 ]w e r e
obtained from GE Healthcare (L i t t l eC h a l f o n t ,U K ) .I f
not otherwise stated, oligonucleotides were used in
transfection mixtures at a final concentration of 100 nM
(in cases where two oligonucleotides were used, each
were used at a final concentration of 100 nM) and deliv-
ered to the cells using Lipofectamine™ 2000 (Invitro-
gen). The same reagent was also used to deliver the
plasmid vectors to the cells. When cells where trans-
fected with both oligonucleotide(s) and plasmid vectors,
the oligonucleotides were always delivered 24 h before
the transfection of the cell with plasmids.
Infectious center assay (ICA) with replication-competent
SFV DNA/RNA layered vectors
ICA on the BHK-21 cells was performed as previously
described [29,43]. A modified ICA protocol was used to
estimate the infectivity of replication-competent DNA/
RNA layered vectors for HeLa cells when SFV isolates
failed to form distinctive plaques. In this case, the HeLa
cells were electroporated with vector DNA using a Bio-
Rad (Hercules, CA, USA) Gene Pulser II (one pulse at
220 V/975 μF), collected and suspended in serum free
growth medium. Ten-fold serial dilutions of the HeLa
cell suspension were prepared in serum-free media and
transferred to plates containing 90-100% confluent
BHK-21 cells. Their incubation and treatment was car-
ried out as previously described [29].
RNA purification and reveres-transcription (RT) PCR
analysis
Total RNA from transfected or infected cells was puri-
fied using TriZol reagent (Invitrogen, USA) and the
Table 1 Combinations of wild-type (WT) and aberrantly
spliced introns used in SFV DNA/RNA layered vectors.
Luc gene
Intron in nsP4
Luc0 LucWT Luc7 Luc6+7
None nc A1 A2 A3
WT B0 B1 Nc nc
C654T C0 nc C2 nc
T705G D0 nc D2 nc
C654C + T705G E0 nc Nc E3
nc: vector not constructed.
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was synthesized using First Strand cDNA synthesis kit
(Fermentas; Vilnius, Lithuania), purified and used as a
template for PCR amplification with primers SF (5’-
TGAAGAAGAGCTGTTTTTACGATCCCTTCA-3’)
and SR (5’-GGTTGGTACTAGCAACGCACTTT-
GAATTTTGTAAT-3’)a n dP h u s i o nH o tS t a r tD N A
polymerase (Finnzymes, Espo, Finland).
Results
Insertion of a thalassemic intron reduces gene expression
from an adenovirus vector
Adenoviruses use alternative splicing to express most of
their essential genes [14]. Although it is possible to
replace the native intron(s) with aberrantly spliced ones,
recombinant adenovirus vectors containing a Luc repor-
ter gene with wt or aberrantly spliced introns were con-
structed to simplify the subsequent analysis. When the
pShuttle-CMV plasmid vectors carrying LucWT or
Luc705 reporters were assayed in HeLa cells, it was
found that the intron with the T705G mutation reduced
reporter-gene expression approximately ten-fold (data
not shown). The observed reduction was nearly half that
previously reported for a very similar assay system [38]
and, therefore, a recombinant intron, containing the
T705G and C654T mutations, was constructed and
inserted into the Luc reporter. It was found that lucifer-
ase expression by Luc6+7 was approximately thirty-fold
Figure 1 Schematic presentation of the SFV DNA/RNA layered vectors. The plasmid backbone of the vector is not shown; CMV,
immediately early promoter of human cytomegalovirus; Rz, hepatitis delta virus negative strand ribozyme; p(A), simian virus 40 late
polyadenylation signal. The nsP1-4, region corresponding to ns-proteins of SFV; Luc, coding sequence of the Luc reporter; 26SG, SG-promoter of
SFV. Arrows in boldface indicate transcription initiation sites of the CMV and 26SG promoters; bent arrows indicate processing of mRNA
transcript by ribozyme and lines indicate noncoding regions of SFV. Sites used for intron insertion are indicated by arrows; inserted introns and
thalassemic mutations present in these introns are indicated under the drawings. DNA/RNA layered replicon vector without (A) or with (B)
frame-shift (FS) mutation (indicated by arrow) in the region corresponding to the nsP4 gene. EGFP, coding sequence of EGFP reporter. (C) DNA/
RNA layered replication-competent vector. “Structural” indicates the region corresponding to structural genes (C-E3-E2-6K-E1) of SFV; wt intron
from rabbit beta-globin gene, inserted in this region, is shown by lines above drawing.
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demonstrates the strong inhibitory effect of the artificial
intron, probably due to the fact that it possesses two
cryptic splicing acceptor sites or because the combina-
tion of these sites activates a common cryptic splicing
donor site more efficiently than a single cryptic acceptor
site. In the context of the recombinant adenovirus infec-
tion, however, both aberrantly spliced introns reduced
luciferase expression more than fifty-fold (data not
shown), indicating that the insertion of a single aber-
rantly spliced intron efficiently downregulated gene
expression from the viral DNA genome.
To demonstrate the effects of SSOs, HeLa cells were
transfected with negative control oligonucleotide
ONINV [42] or a mixture of ON705 and ON654 prior
to infection with the recombinant adenovirus. Consis-
tent with previous observations [42], it was found that
ONINV slightly activated reporter expression, and we
therefore excluded this from further experiments. In
contrast, the mixture of SSOs acted as a much more
potent activator than ONINV. The expression of the
luciferase marker by AdenoLuc705 and AdenoLuc654
+705 was activated three-fold and thirteen-fold, respec-
tively (Figure 2A).
To demonstrate that the rescue was indeed caused by
splice correction, the mRNAs produced from Adeno-
Luc654+705 were analyzed by semiquantitative RT-PCR
(Figure 2B). This assay revealed that the mRNAs from
the Luc6+7 reporter were efficiently spliced because no
product corresponding to unspliced RNA was detected
( d a t an o ts h o w n ) .I nt h ea b s e n c eo fS S O s ,t h ei n t r o n
containing two thalassemic mutations was dominantly
spliced using the splicing site at position 654. Only
small amounts of correctly spliced products were
observed and, surprisingly, no use of the incorrect spli-
cing site at position 705 was detected (Figure 2C). Con-
sistently, the presence of ON705 alone had only very
small but detectable effect on this splicing pattern,
whereas the presence of ON654 moved the splicing site
to position 705, causing a concomitant increase in the
correctly spliced product (Figure 2C). Finally, the mix-
ture of SSOs almost completely blocked the use of both
incorrect splicing sites (Figure 2C). Thus, highly effi-
cient splicing correction was likely the only mechanism
behind the observed rescue of luciferase expression,
which is consistent with the almost complete recovery
of luciferase expression observed in the presence of
SSOs (Figure 2A). Consequently, it seems reasonable to
assume that gene expression from almost any DNA
virus or virus-based vector can be regulated by the
insertion of one or more aberrantly spliced introns in
concert with splicing correction by their matching
SSOs.
Insertion of aberrantly spliced introns reduces the rescue
of replicating RNA from DNA/RNA layered SFV replicon
vectors
The sequences of all positive-strand RNA viruses con-
tain numerous motifs corresponding to cryptic splicing
sites. In the corresponding DNA/RNA layered expres-
sion systems, these cryptic introns have a negative effect
on the efficiency of the vector. Such problems could
likely be solved by the insertion of efficiently spliced
introns into these vectors and/or the removal of cryptic
splicing sites by silent mutagenesis [29,31-34]. However,
even when introns can be used in DNA/RNA layered
vectors, only the rescue of replicating RNA is affected
by their presence but not its subsequent replication and
transcription.
To demonstrate the effect of an aberrantly spliced
intron on the rescue of alphavirus replicons from DNA/
RNA layered vectors, we used SFV vectors carrying an
EGFP gene under the control of the SG promoter (Fig-
ure 1A). In this system, if the introns in LucWT, Luc7
or Luc6+7 reporters are not correctly removed by spli-
cing, the reading frame of the SFV replicase is disrupted.
While the luciferase marker can be expressed from cor-
rectly spliced transcripts produced by the transcription
of the vector plasmid in the cell nucleus and from repli-
cating replicon RNAs produced in the cytoplasm, EGFP
expression is here exclusively mediated by viral replicase
activity (Figure 3A). Thus, the efficiency of replication
can be analyzed by monitoring the expression of these
markers. The corresponding assay revealed that the pre-
sence of an intron with a T705G mutation in an A2 vec-
tor (Table 1) resulted in less than a 50% reduction of
luciferase expression compared to the A1 vector,
whereas intron with two mutations in an A3 vector
resulted in a nearly four-fold decrease of luciferase
expression (Figure 3B). The much smaller effect com-
pared to that observed for adenovirus vectors may be
caused by the replicative nature of the alphavirus-repli-
con RNA. Consistent with this concept, it was observed
that the EGFP signal appeared, albeit at later time
points, in cells transfected with A2 or A3 vectors (data
not shown), indicating that the initiation of RNA repli-
cation was not blocked, only delayed. To prove that dif-
ferences in RNA replication were indeed responsible for
the diminished difference between the vectors with wt
or aberrantly spliced introns, vectors with an FS muta-
tion, preventing expression of functional polymerase and
thus any replication/transcription of replicon RNA, were
constructed and analyzed. The FS mutation reduced
luciferase expression approximately ten-fold (A1FS com-
pared to A1) and, as expected, completely abolished any
EGFP expression. A comparison of luciferase expression
by these vectors revealed that the intron with the
Viru et al. Virology Journal 2011, 8:243
http://www.virologyj.com/content/8/1/243
Page 5 of 13Figure 2 Effects of insertion of an aberrantly spliced intron and SSOs on adenovirus vector. A. Expression of luciferase in HeLa cells
infected by adenovirus vectors containing wt (AdenoLucWT) or aberrantly spliced (AdenoLuc705 and AdenoLuc654+705) intron in the presence
of ONINV (100 nM, open columns) or a mixture of ON654 and ON705 (100 nM, black columns) at 24 h postinfection. The luciferase activities
from both series (ONINV and ON654+ON705 transfected cells) were normalized to the activities obtained for AdenoLucWT infected cells, which
were defined as 100%, and are represented on the vertical axis. Error bars represent standard deviations; experiments were repeated twice with
similar results. B. Schematic presentation of luciferase reporter with recombinant intron and the RT-PCR analysis of splicing products. SF, splice
forward primer; SR, splice reverse primer. Positions of thalassemic mutations and common cryptic splice site (CSS) activated by these mutations
are shown by open arrows. The aberrant and correct splicing possibilities and mRNAs resulting from these processes are shown, and the length
of RT-PCR product is indicated for each splicing variant. C. Agarose-gel electrophoresis analysis of RT-PCR products. SSOs are indicated above the
panel; the sizes of expected DNA fragments are shown at the left.
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Page 6 of 13Figure 3 Effects of insertion of aberrantly spliced introns into SFV DNA/RNA layered replicon vectors.A .S c h e m a t i cp r e s e n t a t i o no f
vectors A2 and A3 (Table 1). Products of correct splicing (left) represent mRNAs for functional replicase of SFV and for the luciferase marker; the
subsequent replication of these RNAs by SFV replicase results in template amplification and transcription of SG-mRNA used for EGFP expression.
mRNAs resulting from aberrant splicing (right) express only P123 polyprotein. B. Luciferase activities in HeLa cells at 24 h after transfection with
vectors A1, A2 and A3 are represented on the vertical axis; luciferase activities in cells transfected with A1 vectors were taken as 100%. Left
panel, results for DNA/RNA layered replicon vectors; right panel, results for DNA/RNA layered replicon vectors containing FS mutation. C.
Luciferase activities in HeLa cells at 24 h after transfection with vectors B0, C0, D0 and E0 are represented on the vertical axis; luciferase activities
in cells transfected with B0 vectors were taken as 100%. Left panel, results for DNA/RNA layered replicon vectors; right panel, results for DNA/
RNA layered replicon vectors containing FS mutation. D. Luciferase activities in HeLa cells at 24 h after transfection with vectors B1, C2, D2 and
E3 are represented on the vertical axis; luciferase activities in cells transfected with B1 vectors were taken as 100%. Left panel, results for DNA/
RNA layered vectors; right panel, results for DNA/RNA layered vectors containing FS mutation. Error bars on panels B-D represent standard
deviations; experiments were repeated three times with similar results.
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mately two-fold and the intron with two mutations
reduced marker expression approximately eight-fold
(Figure 3B). This indicates that replication is important,
but not the sole factor responsible for the relatively
small differences in luciferase expression between A1
and the A2 or A3 vectors. Other factors such as the
reduced stability of luciferase when expressed in the
SFV vector system [44] and/or the toxic effect of nsP2
of SFV on the host cells [45] may also have contributed
to this effect.
Next, the effects of an intron introduced into the nsP4
encoding region of the sequence were analyzed. In this
case, aberrant splicing was not expected to disrupt luci-
ferase expression from mRNA transcripts made in the
nucleus but should still abolish replicase production
and, therefore, also the replication and transcription of
r e s c u e dR N A .I tw a sf o u n dt h a tam u t a n ti n t r o no fa n y
kind only caused a minor (approximately 30%) reduction
in luciferase expression (Figure 3C). This small effect
most probably relates aberrant splicing did not disrupt
the luciferase expression and all mRNAs, either made in
nucleus or produced by viral replicase complexes, con-
tributed to luciferase expression. Similar to the vectors
A2 and A3 the EGFP expression by C0, D0 and E0 vec-
tors was not abolished but slightly delayed. The experi-
ment with corresponding vectors containing FS
mutations revealed nearly twenty fold reduction of luci-
ferase expression (B0FS compared to B0) but expectedly
failed to reveal any significant effect of the intron in
nsP4 region on expression of luciferase (Figure 3C).
Because insertion of one aberrantly spliced intron was
clearly insufficient to suppress the release of autono-
mously replicating transcripts, SFV DNA/RNA layered
replicon vectors containing two introns were con-
structed and analyzed. The results revealed that two
introns with T705G mutations or a combination of
introns with T705G and C654T mutations resulted in a
more than ten-fold reduction of luciferase expression;
two introns containing combination of C654T and
T705G mutations caused a nearly one-hundred-fold
reduction of marker expression (Figure 3D). Thus, com-
bining defective introns resulted in increased inhibition
of the rescue of infectious transcripts. The observed
inhibitory effects were most significant early after trans-
fection and gradually decreased over time. Coherently,
the number of EGFP-positive cells, which was greatly
(approximately twenty fold) reduced at the beginning of
experiment, gradually increas e da tt h el a t e rt i m e p o i n t s .
Consistent with the data from previous experiments, it
was found that in the context of DNA/RNA layered vec-
tors with an FS mutation, the combination of these
introns resulted in inhibitory effects similar to those
observed for FS vectors containing a single aberrantly
spliced intron in the luciferase-reporter region (compare
the right panels of Figure 3B and Figure 3D).
Insertion of aberrantly spliced introns reduces infectivity
of SFV DNA/RNA layered replication-competent vectors
DNA/RNA layered replicon vectors do not produce
infectious progeny, and qualitative infectivity assays are
thus inapplicable for these vectors. Although the inabil-
ity to spread greatly increases the safety of these vectors,
it also limits their use in many important applications
[6]. Therefore, the effects of the insertion of aberrantly
spliced introns on the infectivity of DNA/RNA layered
replication-competent SFV vectors were analyzed. The
vectors used in this study were based on pCMV-SFV4,
which contains a wt intron from the rabbit beta-globin
gene (Figure 1C). However, it was found that the inser-
tion of one or two wt introns from the human beta-glo-
b i ng e n eh a dn oe f f e c to nt h ee f f i c i e n c yo fi n f e c t i o u s
virus rescue from the corresponding constructs (data
not shown), indicating that the different introns did not
interfere with each other.
Next, a set of DNA/RNA layered replication-compe-
tent vectors containing one or two aberrantly spliced
introns (Table 1) was constructed and their infectivity
was tested using ICA in BHK-21 cells. The results of
this analysis (Table 2) showed that the insertion of an
intron with a T705G mutation into the luciferase repor-
ter region reduced the infectivity of the vector by 50%,
while the insertion of an intron with two mutations
resulted in a nearly five-fold drop in infectivity. The
insertion of two aberrantly spliced introns caused more
pronounced effects, ranging from ten-fold reductions for
the C2 and D2 vectors to a fifty-fold reduction for the
E3 vector. When ICA was performed with HeLa cells,
only the constructs lacking an aberrantly spliced intron
produced plaques (Table 2). Taking into account the
detection limit of this experiment, we concluded that
the effect of an aberrantly spliced intron or introns was
greater in HeLa than in BHK-21 cells. This may result
from the fact that the introns with the IVS2
705 and
Table 2 Infectivity of SFV replication-competent vectors
in BHK-21 and HeLa cells (in PFU/pmol of vector DNA).
ell line
Construct
BHK-21 HeLa
A1 1.3 × 10
6 3.6 × 10
4
A2 7.6 × 10
5 Nd
A3 2.8 × 10
5 Nd
B1 1.0 × 10
6 2.4 × 10
4
C2 1.1 × 10
5 Nd
D2 1.0 × 10
5 Nd
E3 2.5 × 10
4 Nd
nd: not detected (below 100 PFU/pmol).
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654 mutations had a human origin and therefore the
mutations had less effect in rodent cells. Alternatively,
the difference may originate from the different efficiency
of the alphavirus DNA/RNA layered vector in different
cell lines, as previously described for DNA/RNA layered
vectors derived from the Sindbis virus [46]. Nonetheless,
the infectivity of the DNA/RNA layered replication-
competent vectors in BHK-21 cells was in accord with
the luciferase expression by DNA/RNA layered replicon
vectors with similar designs in HeLa cells (Table 2; Fig-
ure 3B, D). To test whether this correlation also existed
for replication-competent vectors, the corresponding
vectors were transfected into HeLa cells and the lucifer-
ase activity was measured 16 h later. The results of this
analysis (Figure 4) were consistent with those obtained
using ICA; however, the correlation was lost when luci-
ferase activities were measured 30 h or more post-trans-
fection (data not shown). The presence of a single
aberrantly spliced intron inside the luciferase reporter
region caused three- (A2) to five-fold (A3) reductions in
luciferase expression, while the combination of two
aberrantly spliced introns caused a six- (C2, D2 vectors)
to more than one-hundred-fold (E3) effect (Figure 4).
Thus, luciferase activity can also be used to accurately
estimate the infectivity of the corresponding DNA/RNA
layered replication-competent vectors.
Rescue of the activity of DNA/RNA replicon and
replication competent vectors by SSOs
The effect caused by the insertion of aberrantly spliced
introns can be reversed through the use of SSOs with
plasmid vectors in transfected cells or in stable cell lines
[38] and with recombinant adenovirus vectors (Figure
2A). The reversion depends on the concentration of
SSOs [38] and can be greatly enhanced by applying oli-
gonucleotides with splice-enhancing activities [40,47].
To determine whether this was also the case for SFV
DNA/RNA layered replicon vectors, the activity of an
E3 replicon was analyzed in the presence of ON705 or/
and ON654. Despite the presence of target sites for
both SSOs, they were found to be unequally efficient.
ON705 had, even at concentration of 100 nM, only a
modest effect on the rescue of self-replicating tran-
scripts, whereas in the presence of ON654, activity was
observed rapidly, even at a concentration of 10 nM (Fig-
ure 5). When the SSOs were combined, a synergistic
effect was observed. The rescue was already efficient at
10 nM; it peaked at a 40 nM concentration and did not
change significantly at higher concentrations (Figure 5).
RT-PCR analysis revealed that the splicing pattern of
t h ei n t r o ni nt h eE 3v e c t o r ,a sw e l la st h ee f f e c t so f
SSOs on this pattern, were identical to those observed
with an adenovirus vector (data not shown). This
explains, at least in part, the more prominent effect of
ON654 and suggests that ON654 has some splice-
enhancing activity, even though its target site does not
overlap with the target of the previously characterized
splice-enhancing SSO [47]. Thus, both SSOs were
needed to reverse the effects caused by a combination
of T705G and C654T mutations, and ON654 clearly had
the greater contribution to this rescue effect.
Next, it was confirmed that SSOs were also capable of
rescuing the activity of DNA/RNA layered replication-
competent SFV vectors containing one (data not shown)
or two aberrantly spliced introns (Figure 6). The presence
Figure 4 Effects of insertion of aberrantly spliced introns into
SFV DNA/RNA layered replication-competent vectors. Luciferase
activities in HeLa cells at 16 h after transfection with SFV replication-
competent DNA/RNA layered vectors containing one (A1, A2 and
A3) or two (B1, C2, D2 and E3) introns from the human beta-globin
gene are represented on the vertical axis; luciferase activity in cells
transfected with A1 vector was taken as 100%. Error bars on
represent standard deviations, the results of one reproducible
experiment are shown.
Figure 5 Rescue of the defect caused by insertion of an
aberrantly spliced intron. Rescue of the defect caused by
insertion of an aberrantly spliced intron into DNA/RNA layered
replicon vectors by ON654, ON705 or their combination. HeLa cells
were transfected with the indicated SSOs at final concentrations of
0, 10, 20, 40, 100 or 200 nM 24 h prior to transfection with E3
vector. Luciferase activity (in relative luciferase units) produced by
the vector at 24 h post-transfection is represented on the vertical
axis. Open columns represent activities obtained in the presence of
ON705, gray columns represent activities obtained in the presence
of ON654 and black columns represent activities obtained in the
presence of both SSOs. Error bars represent standard deviations; the
results of one of three reproducible experiments are shown.
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two-fold activation of rescue and/or subsequent replica-
tion of the B1 vector containing only wt introns. A simi-
lar enhancement effect on SFV infection was often
observed when infected cells were treated with Lipofecta-
mine 2000 and scrambled oligonucleotides (our unpub-
lished data). This effect may be caused by changes in the
lipid composition of the plasma membranes and/or
endosomal membranes used for SFV replication [19] due
to lipids included in the transfection reagent. The effects
of SSOs on the DNA/RNA layered replication-competent
vectors containing aberrantly spliced introns were, how-
ever, much more prominent. Again, ON654 invariably
mediated greater activation than did ON705 (Figure 6),
even for the D2-vector bearing only T705G mutations.
Consistent with prior results, the rescue was most effi-
cient when both SSOs were applied. The magnitude of
activation was over twenty times for the D2 and C2 vec-
tors (Figure 6), clearly indicating that most of it origi-
nated from splice correction. The biggest activation (over
one-hundred-fold) was observed for the E3 vector, where
its activity, which in the absence of SSOs was almost at a
background level, was restored to a level comparable to
that of the B1 vector. These results imply that mutants
with even greater defects, for example a larger number of
defective introns, can probably be efficiently rescued with
an appropriate mixture of SSOs.
Discussion
The basics of splice-switch technology were developed
nearly two decades ago and since then the technology
and its variants, such as exon skipping, have been envi-
sioned as potent approaches to the treatment of several
genetic disorders [25,48], inflammation [27] and cancer
[26]. The great potential of this technology, especially
evident after the first successes in in vivo applications,
naturally raised the question of whether the splice-
switch platform is also applicable for viruses and virus-
based vectors. One possible application would be to use
it against viruses that use splicing. In this case, the SSOs
can act as antiviral agents by causing deregulation of
viral gene expression and subsequently block viral infec-
tion. This method may have potential as a new thera-
peutic approach against viruses that are difficult to
target by conventional means, for example, those using
latent infection accompanied with complicated splicing
and minimal protein expression. However, in general,
this method would be unlikely to have advantages over
the inhibition of viral gene expression and replication
using conventional antisense oligonucleotides or siRNAs
Figure 6 Rescue of the activity of the SFV DNA/RNA layered replication-competent vectors by SSOs. HeLa cells were mock transfected
(control cells, indicated as “none”) or transfected with SSOs (ON654, ON705 or their combination) at a final concentration 100 nM 24 hours prior
to transfection with vectors B1, C2, D2 or E3. Infectivity of constructs was indirectly estimated by measuring the luciferase activity at 16 h post-
transfection; luciferase activities, normalized to that in cells transfected with B1 vector in the absence of SSOs (100%), are represented on the
vertical axis. Error bars represent standard deviations; the results of one of three reproducible experiments are shown
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expression of viral proteins [49].
An alternative possibility is to use splice-switch tech-
nology to control the release, gene expression, replica-
tion and virus-induced pathologies for genetically
modified viruses, as demonstrated in this study for the
adenovirus vector and layered DNA/RNA SFV vectors.
Due to the different nature of the systems used, the
impact of splice-switching would be different in each.
When applied to an adenovirus, splice switching gener-
ates permanent control over viral infection, while in the
case of DNA/RNA layered vectors, only the release of
self-replicating RNA genomes or replicons can be con-
trolled. Indeed, it was found that the introduction of
aberrantly spliced introns into a gene-expression unit of
a recombinant adenovirus had a stronger effect (Figure
2A) than a similar insertion made into alphavirus
layered DNA/RNA vectors (Figure 3B, C, 4). The
observed effect was, especially at later time points, com-
pletely lost for replication-competent SFV due to the
subsequent round of infection (data not shown). Thus,
the insertion of a single aberrantly spliced intron was
insufficient to suppress the release of infectious replicon
RNAs or viral genomes from DNA/RNA layered vectors.
Therefore, it is important that the insertion of two aber-
rantly spliced introns into DNA/RNA layered vectors of
SFV resulted in increased effect and efficiently sup-
pressed the release of infectious RNA (Figure 3D, 4).
The infection of cells by an alphavirus can be initiated
by single copy of correctly delivered and released geno-
mic RNA. When the in vitro transcribed RNA is deliv-
ered by transfection, the efficiency is much lower
(typically ~10
7 pfu/pmol of RNA), possibly reflecting the
fact that transfection is not nearly as effective as natural
RNA delivery in infection. That efficiency is often
further reduced by approximately one log for DNA/
RNA layered vectors, probably because of the necessity
to transport the DNA into the nucleus of the cell and to
export produced RNA from the nucleus to the cyto-
plasm where it can initiate replication. Indeed, it has
been demonstrated by the use of stable cell lines con-
taining integrated copies of DNA/RNA layered vectors
that the nuclear export and stability of produced RNA
are likely the critical steps limiting the efficiency of
DNA/RNA layered vectors [46]. It has also been sug-
gested that RNAs made in the nucleus are intrinsically
less efficient in replication initiation than those delivered
by a natural infection route: single-copy transcript made
in the nucleus is generally insufficient to initiate replica-
tion, instead the presence of a minimal threshold level
of RNA transcripts is required [46]. RT-PCR analysis of
splicing products revealed that even in the case of the
“strongest” aberrantly spliced intron, a considerable
amount of correctly spliced products were present,
corresponding to the potentially self-replicating replicon
RNAs. Additionally, the appearance of EGFP in cells
transfected with such DNA/RNA layered replicon vec-
tors was not blocked but delayed. Both of these facts are
consistent with the model suggested by Boorsma et al.,
2003 [46]. Additionally, the threshold level itself may be
higher for DNA/RNA layered vectors containing aber-
rant intron(s). Data obtained for vectors with FS muta-
tions indicates that aberrant splicing did not negatively
affect the transport of mRNA from the nucleus or its
stability (Figure 3C). Thus, these mRNAs, which were
not capable of producing a functional replicase (Figure
3A) but did contain the correct cis-elements required
for replication and transcription, accumulated in trans-
fected cells. It is also known that the alphavirus repli-
case complex, when provided in trans,i sc a p a b l eo f
replicating such templates [18,22] and, therefore, these
RNA molecules may act as defective interfering gen-
omes. The nsP1-3 proteins of SFV and their precursors
are also translated from aberrantly-spliced RNAs and
may have effect on the the formation of functional repli-
case complexes. Combined with their reduced copy
number, this would likely result in a situation in which
the threshold levels of correctly spliced RNAs are
reached at later times. Additionally, the time taken to
reach required threshold levels is limited by the loss or
inactivation of vector DNA or by the death or severe
damage of transfected cells due to the toxic effects of
nsP2 proteins [45] translated from defective RNAs (Fig-
u r e3 A ) .C o n s e q u e n t l y ,t h er e q u i r e dR N At h r e s h o l d
levels may not be reached at all, as was likely the case
for the HeLa cells transfected with replication-compe-
tent DNA/RNA layered vectors (Table 2). Although our
data indicates that the insertion of a larger number of
aberrantly spliced introns will further enhance the sup-
pression of infectious RNA release, there may be no
need to block it completely. A reduction in the rate of
accumulation of correctly spliced RNAs is likely suffi-
cient to block the release of infectious viruses.
Despite the fact that inhibition of adenovirus vector
gene expression by the insertion of aberrantly spliced
introns was straightforward and multiple factors con-
tributed to reduce the release of infectious alphavirus
replicons or genomes, both systems could be efficiently
rescued by SSOs. Interestingly, the rescue by the combi-
nation of two SSOs was always nearly complete, and,
surprisingly, more significant defects caused by aber-
rantly spliced intron(s) led to higher rescue efficiencies
(Figure 2A, C; Figure 6). Because the rescue rate for the
E3 vector (Figure 5) and D2 vector (Figure 6) by ON705
alone was low, we concluded that the presence of SSOs
with splicing-enhancement activity is required to achieve
high-level or even complete reversion of defects caused
by the insertion of aberrantly spliced introns.
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The results of this study show that splice-switching is
feasible for the construction of conditionally activated
systems of different viruses and could be applicable in
vaccination or virus-based gene or anticancer therapy.
The method is straightforward and can be easily com-
bined with other techniques used for the construction
of regulated viral vectors. Unlike most manipulations
made at the level of the replicating genome, the inhibi-
tion of infectious genome rescue cannot be corrected
or compensated by activity of non-proofreading viral
RNA replicase. Thus, the splice-switch technology can
be used to achieve a targeted rescue of the viral gen-
ome from the vectors in cells where SSOs are present.
However, as SSOs cannot affect the subsequent spread
of alphavirus, additional control measures may be
required, such as the insertion of suicide genes [50].
The possibilities for practical application of this
approach depend on the development and improve-
ment of methods for tissue- and cell-type-specific
delivery of SSOs, which act as essential cofactors for
t h er e l e a s ea n d( i nt h ec a s eo fD N Av i r u s e s )p r o p a g a -
tion of such viral vectors.
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